Fig. 2: O-GlcNAcylation controls CDC27 expression and cell survival in MM. | Acta Pharmacologica Sinica

Fig. 2: O-GlcNAcylation controls CDC27 expression and cell survival in MM.

From: Inhibition of CDC27 O-GlcNAcylation coordinates the antitumor efficacy in multiple myeloma through the autophagy-lysosome pathway

Fig. 2

a Gene Set Enrichment Analysis (GSEA) shows the significant enrichment of the O−Glycan Biosynthesis pathway in MM patients. b Images and bar charts show the protein levels of CDC27 and O-GlcNAcylation in MM.1S cells treated with the indicated doses of OSMI-1 for 24 h. c Representative images and bar charts show the immunofluorescence staining of cytoplasmic, and nuclear O-GlcNAc (green) in MM.1S cells treated with 30 μM OSMI-1 for 24 h. Scale bar = 10 μm. d Images and bar charts show the protein levels of CDC27 and O-GlcNAc in MM.1S transfected with 30 nM siOGT for 48 h (left) or treated with 50 nM Thiamet G for 24 h (right). e Bar charts show the viability of MM.1S cells treated with OSMI-1 (upper), siOGT (middle), and Thiamet G (lower). Representative flow images and bar charts show the cell cycle analysis f and apoptosis analysis g of MM.1S cells treated with OSMI-1 (upper), siOGT (middle), and Thiamet G (lower), respectively. All data were obtained from three independent experiments. The data are presented as the means ± SD. One-way ANOVA with Tukey’s multiple comparison test was used in b. Unpaired two-tailed Student’s t test was used in c–g. ns: not significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Back to article page